How the Threat of Six-Figure Visa Fines Is Fueling the Peptide Payment Ban
Across the peptide, compounding, telehealth, wellness and research industries, businesses are being told that they can no longer accept credit cards for products they previously processed without incident.
Merchant accounts are being terminated. Applications are being rejected. Funds are being frozen. Reserves are being imposed. Processors that once welcomed these businesses are suddenly refusing to accept them.
Why?
One major reason may be the enormous financial pressure Visa and other card brands can place on acquiring banks and payment processors.
The card brands do not necessarily need to publish a straightforward statement saying, “All peptide businesses are banned.” If an acquiring bank faces the possibility of assessments reaching six figures for processing a merchant Visa considers improperly registered, inadequately monitored or engaged in impermissible activity, the practical result can be the same.
The bank terminates the merchant rather than risk the fine.
How card-brand enforcement works
Most merchants do not have a direct contractual relationship with Visa. Their merchant agreement is generally with an acquiring bank or payment processor.
That creates an enforcement chain:
Visa → Acquiring Bank → Processor or ISO → Merchant
Visa establishes the rules for using its network. The acquiring bank is responsible for ensuring that its processors, payment facilitators, independent sales organizations and merchants follow those rules.
When Visa identifies potentially illegal or impermissible activity, Visa says that it works through the responsible acquiring bank to investigate the merchant. If the merchant cannot demonstrate compliance, the acquirer may be required to terminate Visa acceptance. Visa Network Integrity
The acquiring bank therefore carries the immediate financial and contractual exposure.
If Visa assesses the bank, the bank may pass that cost to the processor. The processor may then debit the merchant, withhold settlement funds, use an existing reserve or terminate the account.
The threat of assessments reaching $100,000 per month
The Visa Integrity Risk Program, commonly called VIRP, addresses merchants operating in business categories Visa considers to present heightened legal, regulatory or reputational risk.
These merchants may require special registration, enhanced underwriting and continuing monitoring. Acquirers must demonstrate that they understand the merchant’s business model and maintain appropriate controls.
Industry compliance sources report that continued VIRP noncompliance involving an unregistered or improperly managed high-integrity-risk merchant can expose an acquiring institution to assessments of up to $100,000 per calendar month.
That does not mean Visa automatically imposes a $100,000 fine whenever a merchant sells a peptide-related product. The amount and enforcement response depend upon the specific violation, applicable Visa program, region, duration and remediation history.
But the potential exposure changes the bank’s financial calculation.
If an account generates several thousand dollars in monthly processing revenue but could expose the bank to a six-figure assessment, the bank has little financial incentive to conduct a lengthy, individualized legal review. From the bank’s perspective, terminating the merchant may be the safest option.
That is how the threat of a fine can become a practical industrywide ban.
Fraud and disputes create additional exposure
Visa also monitors acquiring banks and merchants through the Visa Acquirer Monitoring Program, or VAMP.
VAMP combines fraud and non-fraud disputes into a broader monitoring framework for card-not-present transactions. Visa monitors activity monthly and can require remediation when an acquirer or merchant exceeds applicable thresholds. Visa VAMP fact sheet
Industry guidance has reported assessments of approximately:
$5 for each qualifying fraud or non-fraud dispute at the Above Standard level
$10 for each qualifying fraud or non-fraud dispute at the Excessive level
At scale, those assessments can become substantial.
Peptide, telehealth and subscription-based wellness businesses can be particularly vulnerable to disputes involving recurring billing, unclear descriptors, shipping delays, refund complaints and customers who do not recognize a charge.
This means a merchant can face pressure from two directions:
Scrutiny concerning whether its products and marketing comply with applicable laws and card-brand rules.
Financial monitoring based on fraud and dispute activity.
Even a business with legitimate products can become commercially undesirable to a bank if its regulatory profile and dispute levels combine to create excessive risk.
The bank may pass the financial damage downstream
Although Visa typically assesses its member acquiring institution, the bank does not necessarily absorb the loss.
Merchant-processing agreements commonly give acquiring banks and processors broad rights to:
Pass card-brand assessments to the merchant
Debit the merchant’s settlement or operating account
Establish or increase a reserve
Withhold unsettled processing funds
Delay the release of existing reserves
Recover investigation and compliance expenses
Terminate processing immediately
Require indemnification for network penalties
Therefore, a Visa assessment directed at the acquiring bank can ultimately become the merchant’s financial problem.
A business may lose its payment account and then discover that thousands—or even hundreds of thousands—of dollars are being held to protect the bank from possible refunds, disputes, card-brand assessments and regulatory exposure.
Is Visa banning every peptide?
The publicly available evidence does not establish that Visa has issued one universal rule prohibiting every peptide-related transaction.
Peptides can be sold through very different business models, including:
Licensed compounding pharmacies
Medical and telehealth providers
Clinical laboratories
Pharmaceutical manufacturers
Academic and commercial research suppliers
Cosmetic and wellness companies
Businesses selling products labeled for research use only
Unlicensed sellers offering products for human consumption
These businesses should not automatically be treated as legally identical.
Nevertheless, when banks and processors fear card-brand assessments, merchants may be grouped together based on keywords, products or perceived industry risk. A compliant medical provider or legitimate research supplier can lose processing access because the processor decides that reviewing the entire category is too expensive or dangerous.
That is not technically the same as a written universal ban—but it can produce the same commercial outcome.
Where does Eli Lilly fit into this?
Eli Lilly has publicly pursued litigation and enforcement efforts involving businesses it alleges are selling unauthorized, counterfeit or unlawful versions of its products.
Lilly has every right to protect its patents, trademarks and patients from unsafe or counterfeit drugs.
However, serious questions remain about whether pharmaceutical companies have pressured payment networks, banks, processors or online platforms to restrict broader categories of peptide-related businesses.
Those questions include:
Did Lilly or its representatives identify merchants to Visa or acquiring banks?
Did payment companies independently investigate those merchants?
Were allegations treated as proven violations?
Were lawful businesses grouped with counterfeit or illegal sellers?
Did the threat of Visa assessments discourage banks from conducting individualized reviews?
Were merchants given meaningful notice and an opportunity to respond?
Did pharmaceutical companies and payment networks coordinate merchant-identification information?
Were payment restrictions used to protect patients, suppress competition—or both?
These questions do not establish wrongdoing by themselves. They demonstrate why affected businesses should preserve evidence and why qualified antitrust and class-action attorneys should investigate.
Card brands should not replace the courts
Counterfeit products, unlawful drug sales and intentionally deceptive businesses should not be protected.
But allegations are not court judgments.
When a private company can report a competitor to a payment network, and the network can place the acquiring bank under threat of massive financial assessments, the accused merchant may be effectively removed from the marketplace before any court or regulator determines that it violated the law.
The merchant loses the ability to accept payments.
The bank freezes its money.
Employees may lose their jobs.
Patients or research customers lose access.
The business may collapse before it ever receives a meaningful opportunity to defend itself.
That is financial blacklisting without traditional due process.
What affected businesses should preserve
If your peptide, compounding, telehealth, wellness or research business has been restricted, preserve:
Termination and suspension notices
Emails from processors and acquiring banks
Notices referencing Visa, Mastercard or card-brand assessments
Reserve and funding-hold notices
Merchant-processing agreements
Application rejection messages
Compliance questionnaires
Website and product screenshots
Licenses and pharmacy documentation
Certificates of analysis and laboratory reports
Supplier and fulfillment records
Legal opinions
Chargeback and refund reports
Communications mentioning Eli Lilly
Evidence of lost sales and other financial damages
Do not alter documents or remove relevant website content without first preserving dated copies.
The exact wording of a processor’s notice may help establish whether an account was terminated because of the merchant’s individual conduct or because of a broader policy affecting an entire industry.
We want to hear from affected businesses
2nd Amendment Processing is gathering information from peptide companies, compounding pharmacies, medical clinics, telehealth providers, research suppliers and payment professionals that have experienced:
Merchant-account termination
Application rejection tied to peptide products
Frozen processing funds
Excessive or unexpected reserves
Warnings about Visa or Mastercard fines
Restrictions involving GLP-1 products
Notices mentioning tirzepatide, semaglutide, retatrutide or related peptides
Lost revenue caused by payment-processing restrictions
Our purpose is to identify patterns, preserve evidence and determine whether sufficient grounds exist to present the matter to qualified class-action and antitrust counsel.
The fines explain the fear—but they do not answer the legal questions
The possibility of assessments reaching $100,000 per month explains why acquiring banks and processors may be unwilling to serve peptide-related businesses.
It does not establish that every affected business was unlawful.
It does not prove that each termination resulted from an individualized investigation.
It does not explain whether outside commercial interests influenced the card brands.
And it does not answer whether lawful competitors were denied access to essential payment infrastructure without due process.
Those questions still demand answers.
When card-brand fines are large enough to frighten banks out of serving an entire industry, the card brands do not need to announce a formal ban. The financial threat does the banning for them.
Important notice: 2nd Amendment Processing is not a law firm and does not provide legal advice. Nothing in this article determines whether a particular product, merchant or processing restriction is lawful. Assessment amounts and program requirements may vary based on the applicable Visa rules, region, violation and enforcement period. Businesses should consult qualified legal and payments professionals regarding their individual circumstances.
Comments